This article is more than 5 years old. Information may no longer be current.

10 takeaways from the ASH Annual Meeting and Exposition

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The ASH Annual Meeting and Exposition featured the latest breakthroughs in treatment — including advances in immunotherapy and gene therapy — as well as advances in prevention and diagnosis of benign and malignant hematologic conditions.

HemOnc Today presents its 10 top takeaways from the ASH Annual Meeting and Exposition that may affect your practice.

• Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy appeared active and safe for children and young adults with relapsed or refractory acute lymphoblastic leukemia, according to interim results of a first-in-human study. Read more.
• CPX-351 (Vyxeos, Celator Pharmaceuticals) conferred better outcomes after allogeneic hematopoietic stem cell transplantation than standard cytarabine and daunorubicin in older patients with high-risk acute myeloid leukemia, according to results of an exploratory analysis of a phase 3 trial. Read more.
• John Sweetenham, MD, executive medical director of Huntsman Cancer Institute at University of Utah and HemOnc Today’s Chief Medical Editor for Hematology, provides an overview of key studies from the meeting that relate to lymphoma treatment. Watch here.
• Oral vancomycin, a standard antibiotic, effectively prevented Clostridium difficile infection in patients undergoing allogeneic HSCT. Read more.
• Vadastuximab talirine was safely combined with 7 + 3 chemotherapy for the induction treatment of patients with AML, according to results of a dose-escalation study. Read more.
• John P. Leonard, MD, of the department of medicine at Weill Cornell Medicine and NewYork-Presbyterian Hospital, provided insights into results of the randomized phase 3 GALLIUM study. Watch here.
• Pacritinib (CTI BioPharma) more effectively led to spleen volume reduction than best available therapy in patients with myelofibrosis and platelet counts less than 100,000/µl, including those who had previously received a JAK2 inhibitor, according to results of the PERSIST-2 trial. Read more.
• Brentuximab vedotin (Adcetris, Seattle Genetics) yielded significantly higher response rates and longer PFS than standard-of-care options for cutaneous T-cell lymphoma. Read more.
• Rebecca A. Gardner, MD, assistant professor at Seattle Children’s Hospital, spoke with HemOnc Today about a study that evaluated an early intervention against cytokine release syndrome among patients with pre-B ALL who underwent anti-CD19 CAR T-cell therapy. Watch here.
• Gene transfer via SPK-9001 achieved sustained mean Factor IX levels greater than 30% without immunosuppression in patients with hemophilia B, according to study results presented during the plenary session. Read more.